Cargando…
Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States
BACKGROUND: There are limited data on economic aspects of the genetic variant of chronic obstructive pulmonary disease (COPD) in the context of the more prevalent form of COPD. The objective of this study was to isolate the healthcare resource utilization and economic burden attributable to the pres...
Autores principales: | Sieluk, Jan, Slejko, Julia F., Silverman, Henry, Perfetto, Eleanor, Mullins, C. Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510284/ https://www.ncbi.nlm.nih.gov/pubmed/32967697 http://dx.doi.org/10.1186/s13023-020-01523-4 |
Ejemplares similares
-
Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients
por: Karl, Florian M., et al.
Publicado: (2017) -
Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
por: Mattingly, T. Joseph, et al.
Publicado: (2019) -
Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
por: Zhumagaliyeva, Ardak, et al.
Publicado: (2017) -
Diagnosing alpha-1 antitrypsin deficiency: does it prevent or improve the course of COPD?
por: Godoy, Irma
Publicado: (2016) -
Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil
por: Russo, Rodrigo, et al.
Publicado: (2016)